{"id":742274,"date":"2013-12-18T07:30:00","date_gmt":"2013-12-18T07:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma\/"},"modified":"2023-03-22T00:04:31","modified_gmt":"2023-03-22T04:04:31","slug":"merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma\/","title":{"rendered":"Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the initiation of a clinical trial to evaluate the<br \/>\n      combination of the company\u2019s investigational anti-PD-1 immunotherapy,<br \/>\n      MK-3475, and GlaxoSmithKline\u2019s orally administered kinase inhibitor,<br \/>\n      pazopanib, in advanced renal cell carcinoma.\n    <\/p>\n<p>\n      \u201cCollaborations like this are central to Merck\u2019s strategy to evaluate<br \/>\n      the potential of MK-3475 for the treatment of cancer,\u201d said Iain Dukes,<br \/>\n      senior vice president, Licensing and External Scientific Affairs, Merck<br \/>\n      Research Laboratories. \u201cWe look forward to initiating further<br \/>\n      collaborations to investigate MK-3475 in combination with other<br \/>\n      anti-cancer agents across a range of tumor types.\u201d\n    <\/p>\n<p>\n      Merck and GlaxoSmithKline entered a collaboration to study MK-3475 with<br \/>\n      pazopanib and other agents in the GlaxoSmithKline portfolio in the<br \/>\n      future. This Phase I\/II clinical trial is designed to evaluate<b> <\/b>the<br \/>\n      safety and efficacy of a combination of MK-3475 and pazopanib<b> <\/b>in<br \/>\n      treatment na\u00efve patients with advanced renal cell carcinoma. Further<br \/>\n      details of the collaboration were not disclosed.\n    <\/p>\n<p>\n      <b>About pazopanib<\/b>\n    <\/p>\n<p>\n      Pazopanib was approved by the US Food and Drug Administration for the<br \/>\n      treatment of patients with advanced renal cell carcinoma in October 2009<br \/>\n      and is marketed under the trade name Votrient\u00ae. It is now approved in<br \/>\n      more than 80 countries. For full US Prescribing Information including<br \/>\n      BOXED WARNING for hepatotoxicity and Medication Guide, please visit: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.gsk.com%2Fproducts.html&#038;esheet=50771024&#038;newsitemid=20131218005352&#038;lan=en-US&#038;anchor=http%3A%2F%2Fwww.gsk.com%2Fproducts.html&#038;index=1&#038;md5=2e3a6ccb857ce7a157ddcb9e362256d0\" rel=\"nofollow\">http:\/\/www.gsk.com\/products.html<\/a>\n    <\/p>\n<p>\n      <b>About MK-3475<\/b>\n    <\/p>\n<p>\n      Many tumors are able to evade the immune system through a mechanism that<br \/>\n      exploits the PD-1 inhibitory checkpoint protein. MK-3475 is an<br \/>\n      investigational, highly selective anti-PD-1 immunotherapy designed to<br \/>\n      restore the natural ability of the immune system to recognize and target<br \/>\n      cancer cells by selectively achieving dual ligand blockade (PD-L1 and<br \/>\n      PD-L2) of the PD-1 protein. By blocking PD-1, MK-3475 enables activation<br \/>\n      of the immune system\u2019s T-cells that target cancer by essentially<br \/>\n      releasing a brake on the immune system.\n    <\/p>\n<p>\n      MK-3475 is being studied in 10 clinical trials estimated to enroll over<br \/>\n      4,000 patients across a broad range of cancer types, including: bladder,<br \/>\n      colorectal, gastric, head and neck, melanoma, non-small cell lung,<br \/>\n      triple negative breast, pancreatic, hematological malignancies and renal<br \/>\n      cell carcinoma. Additional trials, as monotherapy and in combination<br \/>\n      with other cancer therapies, are planned in 2014. For information on<br \/>\n      Merck\u2019s clinical trials please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinical-trials%2F&#038;esheet=50771024&#038;newsitemid=20131218005352&#038;lan=en-US&#038;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinical-trials&#038;index=2&#038;md5=e5f3980b99da3eea3b59d279187db5ea\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/clinical-trials<\/a>\/.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50771024&#038;newsitemid=20131218005352&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=3&#038;md5=bc295c0515b11d8c93bac16c1646c823\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=https%3A%2F%2Ftwitter.com%2FMerck&#038;esheet=50771024&#038;newsitemid=20131218005352&#038;lan=en-US&#038;anchor=Twitter&#038;index=4&#038;md5=664f63f8b20d01612b192acef044c974\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&#038;esheet=50771024&#038;newsitemid=20131218005352&#038;lan=en-US&#038;anchor=Facebook&#038;index=5&#038;md5=a9f384484248ca91eae824f7009b8cd7\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2FMerck&#038;esheet=50771024&#038;newsitemid=20131218005352&#038;lan=en-US&#038;anchor=YouTube&#038;index=6&#038;md5=5761469794341b38f58902e602644e60\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50771024&#038;newsitemid=20131218005352&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=7&#038;md5=9c4719a7d464bad86df988960425c2b7\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20131218005352r1&#038;sid=hq1sf1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Ian McConnell, 908-423-3046<br \/>or<br \/>Claire        Mulhearn, 908-423-7425<br \/>or<br \/>Investors:<br \/>Carol Ferguson,        908-423-4465<br \/>or<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the initiation of a clinical trial to evaluate the combination of the company\u2019s investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline\u2019s orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma. \u201cCollaborations like this are central to Merck\u2019s strategy to evaluate the potential of MK-3475 for the treatment of cancer,\u201d said Iain Dukes, senior vice president, Licensing and External Scientific Affairs, Merck Research Laboratories. \u201cWe look forward to initiating further collaborations to investigate MK-3475 in combination with other anti-cancer agents across a range of tumor types.\u201d Merck and GlaxoSmithKline entered a collaboration to study MK-3475 with pazopanib and other agents in the GlaxoSmithKline portfolio in the future. This Phase I\/II clinical trial is designed to evaluate the safety and efficacy of a combination of MK-3475 and pazopanib in treatment na\u00efve<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-742274","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the initiation of a clinical trial to evaluate the combination of the company\u2019s investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline\u2019s orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma. \u201cCollaborations like this are central to Merck\u2019s strategy to evaluate the potential of MK-3475 for the treatment of cancer,\u201d said Iain Dukes, senior vice president, Licensing and External Scientific Affairs, Merck Research Laboratories. \u201cWe look forward to initiating further collaborations to investigate MK-3475 in combination with other anti-cancer agents across a range of tumor types.\u201d Merck and GlaxoSmithKline entered a collaboration to study MK-3475 with pazopanib and other agents in the GlaxoSmithKline portfolio in the future. This Phase I\/II clinical trial is designed to evaluate the safety and efficacy of a combination of MK-3475 and pazopanib in treatment na\u00efve\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:31+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131218005352r1&sid=hq1sf1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma\\\/\",\"name\":\"Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20131218005352r1&sid=hq1sf1&distro=nx\",\"datePublished\":\"2013-12-18T07:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20131218005352r1&sid=hq1sf1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20131218005352r1&sid=hq1sf1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma\/","og_locale":"en_US","og_type":"article","og_title":"Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the initiation of a clinical trial to evaluate the combination of the company\u2019s investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline\u2019s orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma. \u201cCollaborations like this are central to Merck\u2019s strategy to evaluate the potential of MK-3475 for the treatment of cancer,\u201d said Iain Dukes, senior vice president, Licensing and External Scientific Affairs, Merck Research Laboratories. \u201cWe look forward to initiating further collaborations to investigate MK-3475 in combination with other anti-cancer agents across a range of tumor types.\u201d Merck and GlaxoSmithKline entered a collaboration to study MK-3475 with pazopanib and other agents in the GlaxoSmithKline portfolio in the future. This Phase I\/II clinical trial is designed to evaluate the safety and efficacy of a combination of MK-3475 and pazopanib in treatment na\u00efve","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:31+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131218005352r1&sid=hq1sf1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma\/","name":"Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131218005352r1&sid=hq1sf1&distro=nx","datePublished":"2013-12-18T07:30:00+00:00","dateModified":"2023-03-22T04:04:31+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131218005352r1&sid=hq1sf1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131218005352r1&sid=hq1sf1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-collaborates-with-glaxosmithkline-to-evaluate-novel-combination-regimen-for-advanced-renal-cell-carcinoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"a6ceeaba-2899-4120-8f3c-51541b096db3","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742274","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742274\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742274"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}